XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Subsequent Events - Additional Information (Detail)
$ in Millions
 1 Months Ended
Sep. 03, 2024
USD ($)
Multiple
Sep. 30, 2023
USD ($)
Multiple
Royalty Pharma [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Funding received in exchange of royalty payments | $   $ 150.0
Royalty payment ending period   Dec. 31, 2031
Royalty Pharma [member] | Bottom of range [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Multiple of the purchase price were royalty payment will cease   1.65
Royalty Pharma [member] | Top of range [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Multiple of the purchase price were royalty payment will cease   1.925
Events After Reporting Period [member] | Royalty Pharma [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Funding received in exchange of royalty payments | $ $ 150.0  
Royalty payment ending period Dec. 31, 2029  
Events After Reporting Period [member] | Royalty Pharma [member] | Bottom of range [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Multiple of the purchase price were royalty payment will cease 1.65  
Events After Reporting Period [member] | Royalty Pharma [member] | Top of range [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Multiple of the purchase price were royalty payment will cease 2  
Events After Reporting Period [member] | U.S. YORVIPATH [member]    
Disclosure of non-adjusting events after reporting period [line items]    
Funding received | $ $ 150.0  
Revenue interest payment in percentage in exchange for funding 3.00%